LYMPHOCYTAPHERESIS AND CELLULAR LOGISTICS FOR CAR-T THERAPY IN TWO ASSOCIATED BRAZILIAN CENTERS: A DESCRIPTIVE HEMOTHERAPY ANALYSIS
- 1Rede Américas, São Paulo, SP, Brazil
- 2Grupo Pulsa São Paulo, São Paulo, SP, Brazil
Abstract
Introduction: CAR-T cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies and immune diseases. Before T-cell collection, these patients are usually heavily pretreated, with extensive chemotherapy exposure, high clinical complexity and comorbidities that may compromise lymphocytapheresis and cellular manufacturing. Despite the expansion of CAR-T therapy in Brazil, national data regarding hemotherapy procedures for CD3+ collection and cellular logistics remain limited. Methods: This retrospective observational study included patients undergoing T-cell collection for CAR-T therapy between 2022 and 2026 in two associated Brazilian blood centers. Demographic characteristics, diagnosis, CD3+ cell yield, CAR-T product, transportation logistics, infusion status and process-related outcomes were analyzed. All lymphocytapheresis procedures were performed using the Spectra Optia system. Results: Forty-one patients with a registered collection date were evaluated. Median age was 62 years (24–84), and 26 patients were male (63.4%). Diagnoses included non-Hodgkin lymphoma in 20 patients (48.8%), multiple myeloma in 18 (43.9%), acute lymphoblastic leukemia in 1 (2.4%) and autoimmune diseases in two (4.9%). Median collected CD3+ cell yield was 7.40 × 10⁹ cells (0.002–26.12 × 10⁹). Regarding CAR-T products, 14 patients received axicabtagene ciloleucel (34,1%), 17 ciltacabtagene autoleucel (41,5%), 8 tisagenlecleucel (19,5%) and two rapcabtagene (4,9%) autoleucel. Cellular products were shipped through specialized logistics services with temperature control and traceability. All products intended for ciltacabtagene autoleucel were transported cryopreserved. Overall, 26 patients (63.4%) underwent CAR-T infusion, whereas 5 (12.2%) died before infusion, 8 (19.5%) remained awaiting manufacturing or infusion and two (4.9%) experienced manufacturing or collection failure. Median time from collection to infusion was 56 days (31–401). Conclusion: This two-center experience highlights the critical role of hemotherapy throughout the CAR-T process, including lymphocytapheresis, product handling, cryopreservation and cellular logistics. These findings reinforce the complexity of this population and the importance of integration among hemotherapy services, cellular therapy programs and manufacturing centers to optimize CAR-T access in Brazil.
Related
- A descriptive three-domain limitation count is associated with incident cardiovascular disease across three longitudinal ageing cohorts
- CO065 | THROMBOTIC RISK IS NOT UNIFORM ACROSS APHERESIS SETTINGS: INSIGHTS FROM CAR-T LYMPHOCYTAPHERESIS AND AUTOLOGOUS STEM CELL COLLECTION
- Involvement in Home Cooking Activities Is Inversely Associated with Emotional Problems Among Brazilian Adolescents
- Compositional analysis of genetic ancestry shows that relative proportion of African ancestry is positively associated with fecal myeloperoxidase in Brazilian infants
- Ketoacidosis at Hypoglycemic and Low Glucose Levels Associated with SGLT2 Inhibitor Use: A Descriptive Systematic Review of Published Cases
BibTeX
@article{burlamaqui2026lymphocytapheresis,
title = {{LYMPHOCYTAPHERESIS AND CELLULAR LOGISTICS FOR CAR-T THERAPY IN TWO ASSOCIATED BRAZILIAN CENTERS: A DESCRIPTIVE HEMOTHERAPY ANALYSIS}},
author = {Eduardo BURLAMAQUI and Mirianceli Coelho MENDONçA and Mariana Massarenti LANGHI and Gabriele RITTER and Claudio Carneiro BORBA and Celso Erica ARRAIS and Vinícius MOLLA and Erica Mioto Braz MERCHAN and Waldely Veneziani CALHEIROS and Cesar De Almeida NETO},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.106886},
url = {https://doi.org/10.1016/j.htct.2026.106886},
note = {CC BY},
}
RIS
TY - JOUR
TI - LYMPHOCYTAPHERESIS AND CELLULAR LOGISTICS FOR CAR-T THERAPY IN TWO ASSOCIATED BRAZILIAN CENTERS: A DESCRIPTIVE HEMOTHERAPY ANALYSIS
AU - Eduardo BURLAMAQUI
AU - Mirianceli Coelho MENDONçA
AU - Mariana Massarenti LANGHI
AU - Gabriele RITTER
AU - Claudio Carneiro BORBA
AU - Celso Erica ARRAIS
AU - Vinícius MOLLA
AU - Erica Mioto Braz MERCHAN
AU - Waldely Veneziani CALHEIROS
AU - Cesar De Almeida NETO
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.106886
UR - https://doi.org/10.1016/j.htct.2026.106886
AB - Introduction: CAR-T cell therapy has revolutionized the treatment of relapsed or refractory hematologic malignancies and immune diseases. Before T-cell collection, these patients are usually heavily pretreated, with extensive chemotherapy exposure, high clinical complexity and comorbidities that may compromise lymphocytapheresis and cellular manufacturing. Despite the expansion of CAR-T therapy in Brazil, national data regarding hemotherapy procedures for CD3+ collection and cellular logistics remain limited. Methods: This retrospective observational study included patients undergoing T-cell collection for CAR-T therapy between 2022 and 2026 in two associated Brazilian blood centers. Demographic characteristics, diagnosis, CD3+ cell yield, CAR-T product, transportation logistics, infusion status and process-related outcomes were analyzed. All lymphocytapheresis procedures were performed using the Spectra Optia system. Results: Forty-one patients with a registered collection date were evaluated. Median age was 62 years (24–84), and 26 patients were male (63.4%). Diagnoses included non-Hodgkin lymphoma in 20 patients (48.8%), multiple myeloma in 18 (43.9%), acute lymphoblastic leukemia in 1 (2.4%) and autoimmune diseases in two (4.9%). Median collected CD3+ cell yield was 7.40 × 10⁹ cells (0.002–26.12 × 10⁹). Regarding CAR-T products, 14 patients received axicabtagene ciloleucel (34,1%), 17 ciltacabtagene autoleucel (41,5%), 8 tisagenlecleucel (19,5%) and two rapcabtagene (4,9%) autoleucel. Cellular products were shipped through specialized logistics services with temperature control and traceability. All products intended for ciltacabtagene autoleucel were transported cryopreserved. Overall, 26 patients (63.4%) underwent CAR-T infusion, whereas 5 (12.2%) died before infusion, 8 (19.5%) remained awaiting manufacturing or infusion and two (4.9%) experienced manufacturing or collection failure. Median time from collection to infusion was 56 days (31–401). Conclusion: This two-center experience highlights the critical role of hemotherapy throughout the CAR-T process, including lymphocytapheresis, product handling, cryopreservation and cellular logistics. These findings reinforce the complexity of this population and the importance of integration among hemotherapy services, cellular therapy programs and manufacturing centers to optimize CAR-T access in Brazil.
SN - 2531-1379
SN - 2531-1387
ER -